Rallybio (NASDAQ:RLYB) Major Shareholder Buys $1,687,631.88 in Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc purchased 120,804 shares of the business’s stock in a transaction on Monday, May 4th. The shares were bought at an average cost of $13.97 per share, for a total transaction of $1,687,631.88. Following the completion of the transaction, the insider directly owned 744,683 shares in the company, valued at $10,403,221.51. This trade represents a 19.36% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The shares were bought at an average cost of $14.00 per share, for a total transaction of $491,414.00.

Rallybio Trading Up 2.0%

RLYB traded up $0.28 during midday trading on Wednesday, hitting $14.56. 238,233 shares of the company were exchanged, compared to its average volume of 611,199. The company’s 50 day simple moving average is $9.01 and its 200 day simple moving average is $6.58. The firm has a market capitalization of $77.02 million, a price-to-earnings ratio of -5.69 and a beta of -1.10. Rallybio Corporation has a 1-year low of $2.16 and a 1-year high of $15.31.

Rallybio (NASDAQ:RLYB) last posted its earnings results on Monday, March 16th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.01. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.10 million.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Rallybio to a “hold” rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Rallybio

Several hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC lifted its stake in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after buying an additional 120,892 shares in the last quarter. Citadel Advisors LLC lifted its stake in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares in the last quarter. Geode Capital Management LLC lifted its stake in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares in the last quarter. Susquehanna International Group LLP lifted its stake in Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares in the last quarter. Finally, XTX Topco Ltd lifted its stake in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after buying an additional 38,205 shares in the last quarter. 90.34% of the stock is owned by hedge funds and other institutional investors.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.